In support of our findings, a handful of studies also described enhanced TFEB transcriptional activity by Abl inhibition in other neurometabolic disorders such as ALS or Niemann-Pick type C disease [94, 95]. The gene discussed is ABL1; the disease is Niemann-Pick disease type C.